Fennec Pharmaceuticals (FENC) Stock Forecast, Price Target & Predictions
FENC Stock Forecast
Fennec Pharmaceuticals stock forecast is as follows: an average price target of $15.75 (represents a 200.00% upside from FENC’s last price of $5.25) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
FENC Price Target
The average price target for Fennec Pharmaceuticals (FENC) is $15.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $12.00. This represents a potential 200.00% upside from FENC's last price of $5.25.
FENC Analyst Ratings
According to 12 Wall Street analysts, Fennec Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for FENC stock is 0 'Strong Buy' (0.00%), 11 'Buy' (91.67%), 1 'Hold' (8.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Fennec Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 15, 2024 | Chase Knickerbocker | Craig-Hallum | $17.00 | $7.34 | 131.61% | 223.81% |
| May 15, 2024 | Raghuram Selvaraju | H.C. Wainwright | $15.00 | $7.03 | 113.37% | 185.71% |
| Apr 04, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $10.77 | 67.13% | 242.86% |
| Mar 19, 2024 | Chase Knickerbocker | Craig-Hallum | $18.00 | $11.01 | 63.49% | 242.86% |
| Nov 22, 2022 | - | Cantor Fitzgerald | $12.00 | $9.17 | 30.86% | 128.57% |
| Sep 26, 2022 | - | Wedbush | $19.00 | $7.11 | 167.23% | 261.90% |
The latest Fennec Pharmaceuticals stock forecast, released on May 15, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $17.00, which represents a 131.61% increase from the stock price at the time of the forecast ($7.34), and a 223.81% increase from FENC last price ($5.25).
Fennec Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $17.00 |
| Last Closing Price | $5.25 | $5.25 | $5.25 |
| Upside/Downside | -100.00% | -100.00% | 223.81% |
In the current month, the average price target of Fennec Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fennec Pharmaceuticals's last price of $5.25. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 15, 2024 | Craig-Hallum | Buy | Buy | Hold |
| May 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 22, 2022 | Cantor Fitzgerald | - | Overweight | Upgrade |
| Sep 26, 2022 | Wedbush | Outperform | Outperform | Hold |
| Sep 07, 2022 | JonesTrading | - | Buy | Initialise |
| Sep 07, 2022 | Oppenheimer | - | Outperform | Initialise |
| Sep 07, 2022 | Morgan Stanley | - | Equal-Weight | Initialise |
| Sep 07, 2022 | Jefferies | - | Buy | Initialise |
| Sep 07, 2022 | Needham | - | Buy | Initialise |
Fennec Pharmaceuticals's last stock rating was published by Craig-Hallum on May 15, 2024. The company gave FENC a "Buy" rating, the same as its previous rate.
Fennec Pharmaceuticals Financial Forecast
Fennec Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.00M | $6.51M | $3.33M | $1.68M | $1.53M | - |
| Avg Forecast | $27.97M | $26.94M | $24.87M | $23.83M | $17.04M | $15.24M | $13.61M | $14.39M | $12.02M | $8.75M | $11.05M | $10.21M | $8.66M | $5.33M | $3.72M | $1.84M | $893.80K | $50.00M |
| High Forecast | $33.67M | $32.42M | $29.92M | $28.68M | $20.51M | $18.34M | $16.38M | $17.31M | $14.47M | $14.78M | $13.29M | $12.29M | $10.43M | $6.41M | $4.48M | $2.22M | $1.08M | $54.17M |
| Low Forecast | $24.27M | $23.37M | $21.57M | $20.67M | $14.78M | $13.22M | $11.81M | $12.48M | $10.43M | $5.67M | $9.58M | $8.86M | $7.52M | $4.62M | $3.23M | $1.60M | $775.31K | $46.01M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.22% | 0.89% | 0.91% | 1.72% | - |
Fennec Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $10.21M, with a low forecast of $8.86M, and a high forecast of $12.29M. FENC's average Quarter revenue forecast represents a 2.10% increase compared to the company's last Quarter revenue of $10.00M (Dec 23).
Fennec Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-1.87M | $-915.00K | $-4.55M | $-5.16M | $-6.05M | $-4.36M |
| Avg Forecast | $-3.36M | $-3.24M | $-2.99M | $-2.86M | $-2.05M | $-1.83M | $-1.64M | $-1.73M | $-1.45M | $-1.05M | $-1.33M | $-1.23M | $-1.04M | $-640.43K | $-447.55K | $-221.60K | $-107.42K | $-34.71M |
| High Forecast | $-2.92M | $-2.81M | $-2.59M | $-2.48M | $-1.78M | $-1.59M | $-1.42M | $-1.50M | $-1.25M | $-681.07K | $-1.15M | $-1.06M | $-903.31K | $-555.53K | $-388.22K | $-192.22K | $-93.18K | $-27.77M |
| Low Forecast | $-4.05M | $-3.90M | $-3.60M | $-3.45M | $-2.46M | $-2.20M | $-1.97M | $-2.08M | $-1.74M | $-1.78M | $-1.60M | $-1.48M | $-1.25M | $-770.72K | $-538.60K | $-266.68K | $-129.28K | $-41.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.79% | 1.43% | 10.17% | 23.29% | 56.34% | 0.13% |
undefined analysts predict FENC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fennec Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Fennec Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-2.76M | $-1.87M | $-5.44M | $-7.63M | $-7.79M | $-4.49M |
| Avg Forecast | - | - | - | - | $1.14M | $113.75K | $-793.96K | $198.80K | $-727.93K | $-3.37M | $-682.42K | $-1.57M | $-491.35K | $-3.28M | $-4.28M | $-5.51M | $-7.23M | $-34.97M |
| High Forecast | - | - | - | - | $1.44M | $143.83K | $-657.13K | $251.38K | $-602.48K | $-2.69M | $-564.81K | $-1.30M | $737.02K | $-2.71M | $-3.54M | $-4.56M | $-5.99M | $-27.98M |
| Low Forecast | - | - | - | - | $944.35K | $94.14K | $-1.00M | $164.54K | $-920.43K | $-4.04M | $-862.90K | $-1.98M | $-2.46M | $-4.14M | $-5.41M | $-6.97M | $-9.15M | $-41.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 5.61% | 0.57% | 1.27% | 1.38% | 1.08% | 0.13% |
Fennec Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FENC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Fennec Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $11.14M | $7.19M | $7.83M | $6.85M | $7.47M | $3.68M |
| Avg Forecast | $520.75M | $501.46M | $462.89M | $443.60M | $317.21M | $283.67M | $253.34M | $267.83M | $223.82M | $162.89M | $205.63M | $190.14M | $161.29M | $99.19M | $69.32M | $34.32M | $16.64M | $24.68M |
| High Forecast | $626.69M | $603.48M | $557.05M | $533.84M | $381.74M | $341.38M | $304.88M | $322.31M | $269.35M | $275.18M | $247.46M | $228.81M | $194.10M | $119.37M | $83.42M | $41.30M | $20.02M | $29.62M |
| Low Forecast | $451.71M | $434.98M | $401.52M | $384.79M | $275.16M | $246.06M | $219.76M | $232.32M | $194.15M | $105.49M | $178.37M | $164.93M | $139.91M | $86.04M | $60.13M | $29.77M | $14.43M | $19.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.07% | 0.07% | 0.11% | 0.20% | 0.45% | 0.15% |
Fennec Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $190.14M, based on 1 Wall Street analysts, with a range of $164.93M to $228.81M. The forecast indicates a 1607.47% rise compared to FENC last annual SG&A of $11.14M (Dec 23).
Fennec Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.10 | $-0.07 | $-0.21 | $-0.29 | $-0.30 | $-0.17 |
| Avg Forecast | - | - | - | - | $0.04 | - | $-0.03 | $0.01 | $-0.03 | $-0.12 | $-0.03 | $-0.06 | $-0.02 | $-0.12 | $-0.16 | $-0.20 | $-0.27 | $0.75 |
| High Forecast | - | - | - | - | $0.05 | $0.01 | $-0.02 | $0.01 | $-0.02 | $-0.10 | $-0.02 | $-0.05 | $0.03 | $-0.10 | $-0.13 | $-0.17 | $-0.22 | $0.83 |
| Low Forecast | - | - | - | - | $0.03 | - | $-0.04 | $0.01 | $-0.03 | $-0.15 | $-0.03 | $-0.07 | $-0.09 | $-0.15 | $-0.20 | $-0.26 | $-0.34 | $0.67 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 5.56% | 0.59% | 1.34% | 1.44% | 1.13% | -0.23% |
According to undefined Wall Street analysts, Fennec Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FENC previous annual EPS of $NaN (undefined).
Fennec Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| MOLN | Molecular Partners | $5.08 | $29.00 | 470.87% | Buy |
| FENC | Fennec Pharmaceuticals | $5.26 | $15.75 | 199.43% | Buy |
| EWTX | Edgewise Therapeutics | $18.08 | $48.00 | 165.49% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| OLMA | Olema Pharmaceuticals | $12.27 | $27.00 | 120.05% | Buy |
| LRMR | Larimar Therapeutics | $6.81 | $14.50 | 112.92% | Buy |
| KROS | Keros Therapeutics | $55.04 | $105.00 | 90.77% | Buy |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| IRON | Disc Medicine | $47.35 | $63.17 | 33.41% | Buy |
| HRMY | Harmony Biosciences | $38.81 | $50.67 | 30.56% | Buy |
| JANX | Janux Therapeutics | $49.46 | $59.25 | 19.79% | Buy |
| IKNA | Ikena Oncology | $1.67 | $1.33 | -20.36% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
FENC Forecast FAQ
Is Fennec Pharmaceuticals a good buy?
Yes, according to 12 Wall Street analysts, Fennec Pharmaceuticals (FENC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 91.67% of FENC's total ratings.
What is FENC's price target?
Fennec Pharmaceuticals (FENC) average price target is $15.75 with a range of $12 to $19, implying a 200.00% from its last price of $5.25. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Fennec Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for FENC stock, the company can go up by 200.00% (from the last price of $5.25 to the average price target of $15.75), up by 261.90% based on the highest stock price target, and up by 128.57% based on the lowest stock price target.
Can Fennec Pharmaceuticals stock reach $8?
FENC's average twelve months analyst stock price target of $15.75 supports the claim that Fennec Pharmaceuticals can reach $8 in the near future.
What are Fennec Pharmaceuticals's analysts' financial forecasts?
Fennec Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $60.28M (high $72.54M, low $52.29M), average EBITDA is $-7.244M (high $-6.284M, low $-8.718M), average net income is $659.58K (high $1.18M, low $199.1K), average SG&A $1.12B (high $1.35B, low $973.3M), and average EPS is $0.0242 (high $0.0433, low $0.00729). FENC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $103.61M (high $124.69M, low $89.87M), average EBITDA is $-12.453M (high $-10.802M, low $-14.986M), average net income is $0 (high $0, low $0), average SG&A $1.93B (high $2.32B, low $1.67B), and average EPS is $0 (high $0, low $0).
Did the FENC's actual financial results beat the analysts' financial forecasts?
Based on Fennec Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $21.64M, beating the average analysts forecast of $19.56M by 10.64%. Apple's EBITDA was $-13.005M, beating the average prediction of $-2.351M by 453.19%. The company's net income was $-16.339M, beating the average estimation of $-13.558M by 20.52%. Apple's SG&A was $33.31M, missing the average forecast of $364.13M by -90.85%. Lastly, the company's EPS was $-0.61, beating the average prediction of $-0.497 by 22.82%. In terms of the last quarterly report (Dec 2023), Fennec Pharmaceuticals's revenue was $10M, beating the average analysts' forecast of $8.66M by 15.46%. The company's EBITDA was $-1.868M, beating the average prediction of $-1.041M by 79.40%. Fennec Pharmaceuticals's net income was $-2.756M, beating the average estimation of $-491K by 460.93%. The company's SG&A was $11.14M, missing the average forecast of $161.29M by -93.10%. Lastly, the company's EPS was $-0.1, beating the average prediction of $-0.018 by 455.56%